Ali Asif's Form 4 filing
Protagonist Therapeutics, Inc (PTGX) · filed Sep 13, 2024
- Accession no.
- 0001104659-24-099838
- Filed
- Sep 13, 2024
- Trade date
- Sep 11, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $631.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ali AsifCIK 0001921163 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2024 | Common Stock | SSaleDisposed | −2,203 | $44.59 | −$98,231.77 | 34,960 | Direct | |
| Sep 11, 2024 | Common Stock | MOption exerciseAcquired | +6,000 | $19.19 | +$115,140 | 40,960 | Direct | |
| Sep 11, 2024 | Common Stock | MOption exerciseAcquired | +6,000 | $12.17 | +$73,020 | 46,960 | Direct | |
| Sep 11, 2024 | Common Stock | SSaleDisposed | −12,000 | $44.47F1 | −$533,640 | 34,960 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2024 | Common Stock | MOption exerciseDisposed | −6,000 | $0.00 | $0 | 76,500 | Direct | |
| Sep 11, 2024 | Common Stock | MOption exerciseDisposed | −6,000 | $0.00 | $0 | 45,750 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $44.43 to $44.64. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.